NCT07040956View on ClinicalTrials.gov

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 28, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Head and Neck Squamous Cell CarcinomaLow-dose RadiotherapyImmunotherapyTargeted Therapy

Interventions

DRUG

Tislelizumab

200mg IV Q3W

DRUG

Afatinib

Targeted therapy

RADIATION

Low dose radiotherapy

Radiotherapy

Trial Locations (1)

610000

RECRUITING

Department of Radiation Oncology, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER

NCT07040956 - A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. | Biotech Hunter | Biotech Hunter